Deadly Superbugs Win as Wall Street Flees Makers of Antibiotics
Even as deadly strains of bacteria proliferate around the world, big drugmakers are getting out of the antibiotics market, leaving many new products in the hands of tiny startups. But most new antibiotics for dangerous strains are selling poorly because doctors hold them in reserve until they’re absolutely necessary, concerned about creating drug resistance. And price-sensitive hospitals have been slow to switch to the drugs from cheaper generics.
Join the AMR Insights Ambassador Network today!
Connect to over 650 AMR professionals and students in 65 countries!